No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs2217167 |
chr2:49514731-49514732 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
2 |
rs139121266 |
chr2:49514744-49514745 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs372566230 |
chr2:49514753-49514754 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs566473721 |
chr2:49514762-49514763 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs149932971 |
chr2:49514763-49514764 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
6 |
rs200436449 |
chr2:49514810-49514811 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs57811737 |
chr2:49514811-49514812 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs181629887 |
chr2:49514841-49514842 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs537811812 |
chr2:49514883-49514884 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
10 |
rs556594199 |
chr2:49514917-49514918 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
11 |
rs578184280 |
chr2:49514939-49514940 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs574999353 |
chr2:49514957-49514958 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs554337908 |
chr2:49514958-49514959 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs572484970 |
chr2:49514983-49514984 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
15 |
rs112668625 |
chr2:49514998-49514999 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs376042764 |
chr2:49515022-49515023 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs543709300 |
chr2:49515067-49515068 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
18 |
rs542725291 |
chr2:49515077-49515078 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
19 |
rs561003259 |
chr2:49515158-49515159 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
20 |
rs184879199 |
chr2:49515206-49515207 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
21 |
rs563980222 |
chr2:49515250-49515251 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs12997347 |
chr2:49515263-49515264 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
23 |
rs562676631 |
chr2:49515329-49515330 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
24 |
rs545018225 |
chr2:49515330-49515331 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
25 |
rs533235388 |
chr2:49515352-49515353 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
26 |
rs551335001 |
chr2:49515355-49515356 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
27 |
rs566650030 |
chr2:49515446-49515447 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs145079638 |
chr2:49515450-49515451 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
29 |
rs564899689 |
chr2:49515467-49515468 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs12997593 |
chr2:49515533-49515534 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
31 |
rs374518302 |
chr2:49515551-49515552 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs149123592 |
chr2:49515563-49515564 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs542935938 |
chr2:49515582-49515583 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs1344647 |
chr2:49515633-49515634 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
35 |
rs114287854 |
chr2:49515655-49515656 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs143231340 |
chr2:49515680-49515681 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs553606053 |
chr2:49515688-49515689 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
38 |
rs147868257 |
chr2:49515689-49515690 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs141570077 |
chr2:49515720-49515721 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs1344646 |
chr2:49515776-49515777 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
41 |
rs529911899 |
chr2:49515797-49515798 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs147050596 |
chr2:49515813-49515814 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs138403134 |
chr2:49515871-49515872 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
44 |
rs141941470 |
chr2:49515874-49515875 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
45 |
rs576114484 |
chr2:49515886-49515887 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs543481942 |
chr2:49515928-49515929 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs535957336 |
chr2:49515930-49515931 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
48 |
rs150257486 |
chr2:49515946-49515947 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
49 |
rs138932816 |
chr2:49515951-49515952 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
50 |
rs545291091 |
chr2:49515958-49515959 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|